Susquehanna International Group, LLP Caladrius Biosciences, Inc. Transaction History

Susquehanna International Group, LLP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.41 - $0.74 $10,680 - $19,276	-26,049 Reduced 66.78%	12,958 $7,000
Q1 2022 May 16, 2022	BUY	$0.63 - $1.03 $9,663 - $15,799	15,339 Added 64.81%	39,007 $28,000
Q4 2021 Feb 14, 2022	SELL	$0.83 - $1.22 $193,431 - $284,321	-233,050 Reduced 90.78%	23,668 $20,000
Q3 2021 Nov 15, 2021	BUY	$1.15 - $1.57 $275,490 - $376,104	239,557 Added 1395.94%	256,718 $313,000
Q2 2021 Aug 11, 2021	SELL	$1.4 - $1.9 $119,146 - $161,699	-85,105 Reduced 83.22%	17,161 $28,000
Q1 2021 May 17, 2021	BUY	$1.44 - $2.89 $116,020 - $232,847	80,570 Added 371.36%	102,266 $197,000
Q4 2020 Feb 16, 2021	SELL	$1.39 - $1.87 $57,931 - $77,935	-41,677 Reduced 65.76%	21,696 $31,000
Q3 2020 Nov 16, 2020	BUY	$1.6 - $3.0 $101,396 - $190,119	63,373 New	63,373 $114,000
Q1 2020 May 15, 2020	SELL	$1.21 - $3.47 $24,736 - $70,937	-20,443 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$2.02 - $2.85 $41,294 - $58,262	20,443 New	20,443 $51,000

Ticker CLBS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,583,200
Market Cap $25.8M
Description
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical li...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.